INFORMAZIONI PERSONALI Nome ALETTI Giovanni Damiano Cittadinanza ITALIANA Data di nascita 30/10/1973

CURRICULUM FORMATIVO Studi compiuti – Titoli di studio 1992 - Diploma di scuola secondaria superiore (maturità scientifica), presso Liceo Scientifico

"Sacro Cuore", Milano. Voto conseguito: 60/60

1998 - Laurea in Medicina e Chirurgia presso Università degli Studi di Milano

Tesi: Role of Urokinase Receptor (u-PAR) in Ovarian Cancer Voto conseguito: 110/110 e lode

1999 - Abilitazione all'esercizio medico e chirurgo presso Università degli Studi di Milano - Iscrizione all’Ordine dei Medici di Milano 2004 - Diploma di scuola di specializzazione in Ostetricia e Ginecologia presso Università

Vita Salute S.Raffaele/Fondazione San Raffaele del Monte Tabor, Milano Titolo della Tesi: Presence Of Serine Protease HtrA1 Confers Cisplatin Sensitivity In Ovarian Cancer Cell Lines

- Voto conseguito: pieni voti assoluti con lode 2005 - Abilitazione all'esercizio medico e chirurgo negli Stati Uniti certificato da ECFMG –

Educational Commission for Foreign Medical Graduates 2009 - Fellowship in Oncologia Ginecologica presso la Mayo Clinic in Rochester, Minnesota 2012 - Abilitazione Scientifica Nazionale Settore Concorsuale 06/H1 - I Fascia

Certificata da: Ministero dell’Istruzione, dell’Università e della Ricerca - ROMA

E U R O P E A N M O D E L

C U R R I C U L U M V I T A E

- Abilitazione Scientifica Nazionale Settore Concorsuale 06/H1 - II Fascia Certificata da: Ministero dell’Istruzione, dell’Università e della Ricerca - ROMA

Esperienze Formative Allievo (pre-laurea) 1995-1996 Frequenza in qualità di studente interno presso il Dipartimento di Medicina Interna, Padiglione “L.Sacco”, Ospedale Policlinico – Università di Milano 1996 - Frequenza in qualità di studente interno presso il Dipartimento di Chirurgia Generale, Padiglione “Monteggia”, Ospedale Policlinico – Università di Milano 1996-1998 - Frequenza in qualità di studente interno presso il Dipartimento di Ostetricia e Ginecologia, Ospedale San Raffaele – Università di Milano – Durante il periodo come studente interno presso il reparto di Ginecologia diretto dal Prof. Ferrari, si è dedicato in modo particolare al settore della Ginecologia Oncologia, assistendo i principali interventi chirurgici ginecologici, seguendo l’Ambulatorio di Oncologia Ginecologica, e il reparto di Oncologia Ginecologica, acquisendo le principali nozioni riguardo all’utilizzo e alla modalità di somministrazione dei diversi farmaci chemioterapici per le diverse patologie ginecologiche. Ha inoltre partecipato attivamente alle riunioni multidisciplinari di discussione dei casi clinici. Formazione Post-Laurea Fellowship di ricerca 9/2003-9/2004 Basic Research Fellowship presso la Mayo Clinic, Rochester, MN. Focus della fellowship: Role of the tumor suppressor gene HtrA1 in ovarian cancer chemosensitivity, sotto la supervisione e il training di laboratorio da parte della Prof. Viji Shridhar, PhD. Clinical Research Fellowship presso la Mayo Clinic, Rochester, MN. Focus della fellowship: Role of surgical effort in the management of ovarian cancer sotto la supervisione del Dr. William Cliby, MD. 12/2005-6/2006 Research fellowship Mayo Clinic, Rochester, MN. Focus della fellowship: Role of folate receptor in ovarian cancer, sotto la supervisione del Dr. William Cliby, MD. Formazione statistica/scientifica Durante questi periodi di formazione, ha partecipato a corsi di statistica medica, medical writing and prsentation, acquisendo una capacità di utilizzare programmi di statistica (JMP, SAS), e indipendenza nell’eseguire analisi statistiche per studi clinici Fellowship clinica 6/2006-6/2009 Clinical Fellowship in Gynecologic Oncology presso la Mayo Clinic, Rochester Minnesota (Direttore della Fellowship: Dr. William Cliby) Il percorso formativo della fellowship prevede un anno di ricerca di laboratorio, in cui ha proseguito gli studi clinici e di ricerca di base iniziati precedentemente. I due anni successivi di formazione clinica prevedono l’apprendimento della gestione delle

patologie ginecologiche dal punto di vista diagnostico/terapeutico, con rotazioni presso diversi Dipartimenti (Chirurgia Gineco-Oncologica: 20 mesi, Chirurgia Colo-Rettale: 1.5 mesi, Chirurgia Generale: 1.5 mesi, Terapia Intensiva: 1 mese, Oncologia Medica: 1.5 mesi; Radioterapia: 1.5 mesi). Posizione e incarichi attuali 1/2/2018 – oggi - Professore Associato in Ostetricia e Ginecologia (MED/40), presso il Dipartimento di

Oncologia ed Emato-Oncologia, Università degli studi di Milano 1/11/2017-oggi - Direttore dell’Unità di Strategie Innovative nel Carcinoma Ovarico, presso Istituto

Europeo di Oncologia (IRCCS), Divisione di Ginecologia Oncologia 1/8/2009-oggi - Co-Responsabile clinico del Centro di Alta Specialità per il Trattamento del

carcinoma Ovarico presso Istituto Europeo di Oncologia (IRCCS), Divisione di Ginecologia Oncologia (Centro di Eccellenza con certificazione ESGO – European Society of Gynecologic Oncology – www.esgo.org)

- Tutor e istruttore di chirurgia oncologica nell'ambito della fellowship di Ginecologia Oncologica certificata ESGO (European Society of Gynecologica Oncology – www.esgo.org) e di ESAGON (European school of Abdominal Pelvic Surgery) presso Istituto Europeo di Oncologia (IRCCS), Divisione di Ginecologia Oncologia

Ruoli assistenziali precedenti 1/8/2009-31/10/2017 - Vice-Direttore (Dirigente Medico a tempo indeterminato) presso Istituto Europeo di

Oncologia (IRCCS), Divisione di Ginecologia Oncologia 01/02/2005 - 30/11/2005 - Consulente specialista (Dirigente Medico libero professionista) in Ostetricia e

Ginecologia presso Ospedale San Raffaele (IRCCS) – Milano 07/1/2005-28/2005 - Ha partecipato come volontario Ginecologo e Ostetrico al progetto di creazione di

Ospedale da campo in Sri Lanka, dopo lo Tsunami, con mansioni cliniche e organizzative, in collaborazione con l’Ospedale san Raffaele di Milano e il C.A.I. sezione di Bergamo

Attività clinica 1999-2004 Ha svolto attività clinica durante la Scuola di Specializzazione in Ostetricia e Ginecologia presso l’Ospedale S.Raffaele di Milano (6 mesi presso l’Istituto Clinico Humanitas, Rozzano), con svolgimento di attività di Sala Parto, Pronto Soccorso Ostetrico-Ginecologico, Reparti di Ostetricia e Ginecologia, Sala Operatoria Ginecologica e Ostetrica. Durante la formazione come specializzando in Ostetricia e Ginecologia, ha sviluppato le competenze per una autonomia clinica di base sia in ambito ostetrico che ginecologico. Nel suddetto periodo, si è dedicato con prevalente interesse all’Oncologia Ginecologica, ai percorsi diagnostico-assistenziali e al trattamento chirurgico e medico delle patologie gineco-oncologiche, con prevalente interesse per il tumore ovarico. 6/2007-6/2009 Ha svolto attività clinica nel percorso formativo della Fellowship in Ginecologia Oncologica presso la Mayo Clinic, Rochester, MN (USA). Durante questo periodo ha appreso le principali tecniche chirurgiche (laparotomia, laparoscopia, chirurgia robotica

e laparoscopia) per il trattamento delle neoplasie ginecologiche. Al termine del processo formativo, della fellowship ha acquisito un’indipendenza operatoria nelle principali tecniche chirurgiche. Ha infatti effettuato, prima sotto tutoraggio diretto dei Mentori, e successivamente come primo operatore/tutor più di 70 interventi di citoriduzione primaria per neoplasia ovarica , incluso resezioni del retto-sigma e anastomosi e/o resezioni ileali con anastomosi, confezionamento di stomie derivative, deperitoneizzazione diaframmatica e parietale, omentectomia radicale, splenectomia, linfadenectomia pelvica e aortica, nel contesto della chirurgia citoriduttiva per tumore ovarico. Nel contesto del tumore del corpo uterino, ha acquisito indipendenza nella tecnica di isterectomia laparotomica e vaginale, isterectomia laparoscopica e robotica, e stadiazione linfonodale pelvica e aortica in laparotomia e chirurgia robotica (>50 interventi). Ha inoltre appreso la tecnica per l’isterectomia radicale laparotomica e robotica per il trattamento del tumore del collo dell’utero (>20 interventi), e la tecnica di vulvectomia radicale con dissezione linfonodale inguinale (>5 interventi). Oltre all’attività di sala operatoria, l’attività clinica ha previsto la valutazione preoperatoria e la discussione collegiale delle pazienti per l’indicazione chirurgica, e la successiva gestione postoperatoria delle pazienti nel decorso post-operatorio, con particolare enfasi sulla gestione delle complicanze e sulle indicazioni ai trattamenti successivi (chemioterapia o radioterapia), con i Medici Referenti delle Divisioni di Oncologia Medica e Radioterapia 1/8/2009-oggi Dal termine della fellowship, ha assunto responsabilità cliniche come Vice-Direttore (Dirigente Medico prima con contratto libero professionale e successivamente con contratto a tempo indeterminato) presso l’Istituto Europeo di Oncologia (IRCCS), Divisione di Ginecologia Oncologia, diretta dal Dr. Angelo Maggioni. Durante questo periodo ha svolto più di 850 di chirurgia maggiore come primo operatore, più di 650 come secondo operatore/tutor. Dal 1/11/2017 ha assunto il ruolo di Direttore dell’Unità di Strategie Innovative nel Carcinoma Ovarico. Attività didattica 1/2/2018 – oggi - Professore Associato in Ostetricia e Ginecologia (MED/40), presso il Dipartimento di

Oncologia ed Emato-Oncologia, Università degli studi di Milano 05/2012-oggi - Attività didattica come Tutor e istruttore di chirurgia oncologica nell'ambito della

fellowship di Ginecologia Oncologica presso l’Istituto Europeo di Oncologia. Il programma di fellowship è certificato dalla ESGO (European Society of Gynecologica Oncology – www.esgo.org). L’attività didattica prevede l’insegnamento frontale in sala operatoria con il discente fino all’apprendimento delle tecniche chirurgiche ginecologiche-oncologiche e dell’approccio multidisciplinare alle pazienti con tumori ginecologici, dell’approccio diagnostico/terapeutico alle pazienti con tumori ginecologici. Numero dei discenti fino ad oggi: 10, numero dei discenti certificati: 1

01/08/2009 - oggi - Attività didattica come Tutor e istruttore di chirurgia oncologica nell'ambito ESAGON

(European school of Abdominal Pelvic Surgery) presso Istituto Europeo di Oncologia (IRCCS), Divisione di Ginecologia Oncologia. L’attività didattica prevede l’assistenza del discente all’attività di sala operatoria con apprendimento dell’approccio multidisciplinare alle pazienti con tumori ginecologici. L’attività didattica prevede lezioni teoriche a piccoli gruppi (numero lezioni tenute: 20) e corsi di chirurgia su cadavere (numero lezioni tenute: 2) / animali (numero lezioni tenute: 1)

01/08/2009 – oggi - Attività didattica nell’ambito della Scuola Infermieristica, nel Master Infermieristico

e attivita’ di aggiornamento allo Staff Infermieristico di Reparto c/o Istituto Europeo di Oncologia

30/06/2008 - 30/06/2009 - Attività di tutoraggio e insegnamento agli specializzandi (residents) di Ginecologia e

Ospetricia e agli specialisti in formazione in Oncologia Ginecologica (fellows) dei primi 2 anni nell'ambito della fellowship in Oncologia Ginecologica presso la Mayo Clinic in Rochester, Minnesota

BIBLIOGRAPHY Presentazioni/inviti a congressi nazionali/internazionali 24/04/2001 - Tension Free Vaginal Tape in the Treatment of Urinary Stress Incontinence after Radical Surgery and Following Radiotherapy 12th International Meeting of Gynecological Oncology (ESGO) – Venezia 19/04/2002 - Bowel Occlusion in Advanced Ovarian Cancer: Medical And Surgical Care - Ovarian Cancer Updating – Bergamo 23/03/2005 - Ovarian cancer surgical resectability: relative impact of disease, patient status and surgeon. Focused Plenary oral presentation. SGO Annual Meeting on Women's Cancer – Miami, FL 20/03/2005 - Impact of diaphragm resection on outcomes in ovarian cancer. Focused Plenary oral presentation. SGO Annual Meeting on Women’s Cancer – Miami, FL 18-23/03/2005 - Extent of surgical effort is an independent predictor of survival in advanced ovarian cancer. Featured Poster presentation. SGO Annual Meeting on Women’s Cancer – Miami, FL. 26/03/2006 - Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only? Focused Plenary oral presentation. SGO Annual Meeting on Women's Cancer – Palm Springs, CA 22-26/03/2006 - Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Featured Poster presentation. SGO Annual Meeting on Women’s Cancer – Palm Springs, CA 22-26/03/2006 - Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. Featured Poster presentation. SGO Annual Meeting on Women’s Cancer – Palm Springs, CA 03-07/03/2007 - A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a

risk-adjusted model. Plenary Oral presentation. SGO Annual Meeting on Women’s Cancer – San Diego, CA 3-7/03/2007 - Assessing quality and effectiveness of surgery for ovarian cancer: Benefits of a risk adjustment model. Featured Poster presentation. SGO Annual Meeting on Women’s Cancer – San Diego, CA 3-7/03/2007 - Stage IV ovarian cancer: Disease site-specific considerations for postoperative treatment. Featured Poster presentation. SGO Annual Meeting on Women’s Cancer – San Diego, CA 12-14/04/2007 - Analysis of factors contributing to complications in ovarian cancer surgery: need for risk-adjustment model of surgical outcomes. Oral presentation. SGS Annual Meeting – Orlando, FL 06/2007 Role of serine protease HtrA1 in ovarian cancer progression and metastasis. Oral Presentation. WAGO annual meeting – Sunriver, OR 04/2008 - Aggressive and Complex Surgery for Advanced Ovarian Cancer: An Economic Analysis. Oral presentation SGS Annual Meeting – Savannah, GA 31/05/2008 - “Debulk or not debulk?” An answer to an hamletic dilemma using a multi-institutional risk-adjusted model for evaluation of outcomes. ASCO annual Meeting – Chicago, IL 13/10/2008 Quality improvement (QI) in the surgical approach to advanced ovarian cancer (OC): the Mayo Clinic experience. Oral presentation American College of Surgeons Annual Meeting – San Francisco, CA 28/10/2008 Quality improvement (QI) in the surgical approach to advanced ovarian cancer (OC): the Mayo Clinic experience. Oral presentation 12th Biennial Meeting International Gynecologic Cancer Society – IGCS; Bangkok,Thailand 25-28/10/2008 Pattern of retroperitoneal dissemination of primary peritoneum cancer: Basis for rational use of lymphadenectomy. Poster presentation. 12th Biennial Meeting International Gynecologic Cancer Society – IGCS; Bangkok,Thailand 25-28/10/2008 “Debulk or not debulk?” An answer to an hamletic dilemma using a multi-institutional risk-adjusted model for evaluation of outcomes.Poster presentation. 12th Biennial Meeting International Gynecologic Cancer Society – IGCS; Bangkok,Thailand 6/2/2009 Intraperitoneal Chemotherapy for Ovarian Cancer: Exploring the “Dark Side” of the Moon. Oral Presentation. SGO Annual Meeting on Women’s Cancer; San Antonio, TX. 29/5/2010 Robotics in gynecologic surgery: fact or myth? – oral presentation IX International Biannual Meeting S.E.G.i - Maratea, Italy

16/12/2010 Treatment of early stages ovarian cancer – oral presentation Updates on Ovarian Cancer - Rome, Italy 1/04/2011 Role of Minimally invasive surgery in Ovarian Cancer – oral presentation M.I.T.O. Meeting (Multicenter Italian Trials in Ovarian Cancer) - Pisa, Italy 14/09/2011 How extensive should surgery be for advanced ovarian cancer: what is the optimal timing for frontline surgery in ovarian cancer: upfront or following chemotherapy? Surgeon’s perspective – oral presentation 17th International Meeting of the European Society of Gynecologic Oncology (ESGO) - Milan, Italy 15/10/2011 Surgical training in Gynecologic Oncology – How to bring to Italy the US experience – oral presentation 24th National Meeting of the Italian Society of Young Surgeons (SPIGC) - Napoli, Italy 16/11/2011 Center of Excellence for ovarian cancer patients: what does the patient gain? – oral presentation Stockholm, Sweden 16/11/2011 Standards and Quality Criteria for Ovarian Surgery – oral presentation 6th International Conference of Biologic Therapy Vilnius, Lithuania 20/03/2012 Primary Cytoreduction in Ovarian Cancer: Results and Morbidity – oral presentation 23rd National Conference of the Italian Society of Gynecologic Oncology – Verona, Italy 13-14/04/2012 There are still Indications for Lymphadenectomy in Endometrial Cancer 2012 Progress and controversies in Gynecologic Oncology Conference - Barcelona, Spain 10/08/2012 Gynecologic Oncology: Myths and pitfalls. Primary Debulking XX FIGO World Congress of Gynecology and Obstetrics - Rome, Italy 10/08/2012 Robotic Surgery in Gynecologic Oncology XX FIGO World Congress of Gynecology and Obstetrics - Rome, Italy 02/15-16/2013 Treatment for locally advanced early IIB cervical cancer: Neoadjuvant therapy vs radiotherapy. Pro neoadjuvant therapy 2013 Progress and controversies in Gynecologic Oncology Conference - Istambul, Turkey 03/22-23/2013 Surgery in recurrent ovarian carcinoma: an update on ongoing clinical trials Congress: Controversies in the treatment of recurrent ovarian carcinoma - Catania, Italy 04/05/2013 Anatomic-surgical approach to patients with advanced ovarian cancer Role of surgery in recurrent ovarian carcinoma Congress: New strategies in the management of patients with ovarian cancer: from conservative to radical surgery - Giussano, Italy

04/11-12/2013 MIS in Oncologic Surgery: results from a single center changing the surgical approach: Robotic radical hysterectomy 2013 XIV Congress of the Slovakian Society of Gynecologic Endoscopy - Levice, Slovakia 6/19-21/2013 Indications and limits of the conservative treatment of gynecologic malignancies: ovarian cancer VIII National Meeting S.E.G.i, Napoli, Italy 06/27-29/2013 Indications for conservative treatment in stage IB cervical carcinoma Complications of Minimally Invasive Surgery for Gynecologic Malignancies 24th National Conference of the Italian Society of Gynecologic Oncology – Pisa, Italy 09/05-06/2013 - How to implement effective screening in low income countries - Surgical paradigm in the treatment of invasive cervical cancer - Advanced and metastatic cervical cancer: palliative treatment The Breast Cancer and Gynae Cancers Workshop – European School of Oncology (ESO) – The African Organization for Research and Training in Cancer (AORTIC) – Khartoum, Sudan, Africa 10/19-22/2013 Identification of ovarian cancer patients at high risk of surgical morbidity and mortality 18th International Meeting of the European Society of Gynecologic Oncology (ESGO) - Liverpool, UK 10/19-22/2013 Fertility sparing surgery in gynecological cancer: state of the art – ovarian cancer SIOG session - 18th International Meeting of the European Society of Gynecologic Oncology (ESGO) - Liverpool, UK 10/25/2013 Pros and Cons of neoadjuvant treatment in advanced ovarian cancer - Debate Therapy Evolution for Advanvced ovarian cancer Management (TEAM) course – Milano, Italy 04/25-26/2014 Surgical approach of ovarian cancer – Pre-surgical evaluation: tumor diffusion, selection criteria for surgical cytoreduction vs . neoadjuvant chemotherapy - Surgical techniques for optimal cytoreduction - The role of surgery for relapsing ovarian cancer In depth-Review of Ovarian Cancer Diagnosis & Treatment Mendoza, Argentina 05/19-21/2014 Primary surgical treatment: aims and technique 25th National Conference of the Italian Society of Gynecologic Oncology (SIOG) – Siracusa, Italy 06/11/2015 HOW CRS-PP, HIPEC AND NEW DRUGS CAN INFLUENCE THE TREATMENT CHOICE Primary EOC: Up-front CRS+ADCT vs NACT+CRS +/- HIPEC • Medical Point of view Conference: PERITONEAL METASTASES FROM COLORECTAL AND OVARIAN CANCER: THE TURNING POINT? – Humanitas, Rozzano, Italy

16/10/2015 Radical pelvic surgery: costs and benefits Congress: Management of female tumors between needs and economy - Torino, Italy 10/19-21/2015 Upfront Surgery in advanced ovarian cancer 90° National Meeting S.I.G.O (Italian Society of Obstetrics and Gynecology) 10/19-21/2015 Vulvar cancer surgery: prevention and management of complications 90° National Meeting S.I.G.O (Italian Society of Obstetrics and Gynecology) 10/24-26/2015 Advanced Ovarian Cancer: how to select patients in an appropriated and dedicated surgical Center? 19th International Meeting of the European Society of Gynecologic Oncology (ESGO) – Nice, Fr 12/04/2015 Impact of Morcellation on survival of patients with an unespected diagnosis of uterine leiomyosarcoma: a systematic review and a metanalysis 6th Tropè-Kolstad Meeting Oslo, Norway 12/11/2015 Fragile patients: How to Best Select and Sequence Surgery and Chemotherapy for Optimal Outcome M.I.T.O. Meeting (Multicenter Italian Trials in Ovarian Cancer) - Rome, Italy 01/22-23/2016 Neoadjuvant chemotherapy versus primary radiochemotherapy in FIGO IB2 cervical cancer. Pro neoadjuvant therapy 2016 Progress and controversies in Gynecologic Oncology Conference - Barcelona, Spain 02/12-13/2016 Debulking operations in the left upper abdomen: how to do it Master of disaster: complication in Senology and Gynecologic Oncology - Essen, Germany 02/12-13/2016 Clinical and radiologic assessment of feasibility of cytoreduction 5th MD Anderson International Meeting in Gynecologic Oncology: tailoring cancer therapy in the era of personalized therapy - Madrid, Spain 04/14-15/2016 LIVE surgery: robotic total hysterectomy-BSO, pelvic lymphadenectomy ESMO-ESTRO-ESGO - new guidelines on endometrial cancer 2016 XVII Congress of the Slovakian Society of Gynecologic Endoscopy - Nízke Tatry, Slovakia 09/16/2016 Le frontiere della chirurgia in Ginecologia Oncologica – La gestione postoperatoria delle complicanze chirurgiche 27th National Conference of the Italian Society of Gynecologic Oncology (SIOG) – Catanzaro, Italy 10/21-22/2016 LIVE surgery: robotic total hysterectomy-BSO, pelvic lymphadenectomy ESGO/ESMO/ESTRO guidelies and the “newness” of the sentinel node in endometrial cancer 2016 Annual Congress of the Czech Society of Gynecologic Endoscopy - Olomouc, Czech Republic

01/20-21/2017 How to define, evaluate, and identify surgical quality - Viewpoint of the ESGO Quality Assurance Committee 2017 Progress and controversies in Gynecologic Oncology Conference - Barcelona, Spain 02/10-11/2017 Anastomotic leakage and secondary leakage after re-laparotomy. How to manage the disaster of the disaster? Master of disaster: complication in Senology and Gynecologic Oncology - Essen, Germany 05/11/2017 Cervical Cancer - Neoadjuvant and adjuvant chemotherapy in cervical cancer Leaping Forward Oncology - International Clinical Congress – Lisbon, Portugal 06/22/2017 Ovarian Cancer–Hot Topics in Surgical Treatment - Frailty and Surgical Complexity score in the decision making process 28th National Conference of the Italian Society of Gynecologic Oncology (SIOG) – Milano, Italy 09/21-22/2017 Terapia del Tumore Ovarico: Criteri di selezione e Obiettivi della Citoriduzione Primaria 2nd Regional Meeting of Gynecologic Oncology (Sardinia) – Gavoi, Italy 11/05-07/2017 Advanced Ovarian Cancer: Tumor Board 20th International Meeting of the European Society of Gynecologic Oncology (ESGO) – Vien, Austria 11/05-07/2017 Fellows Workshop: Radical Omentectomy and Splenectomy 20th International Meeting of the European Society of Gynecologic Oncology (ESGO) – Vien, Austria 11/05-07/2017 Fellows Workshop: How to select patients for upfront debulking surgery (PET vs CT vs diagnostic laparoscopy) 20th International Meeting of the European Society of Gynecologic Oncology (ESGO) – Vien, Austria 11/24/2017 Lettura magistrale: Stato attuale della terapia chirurgica del carcinoma ovarico 7th Annual Meeting of the Italian School of Minimally Invasive Gynecologic Surgery (SICMIG) – Lido di Camaiore, Italy 06/22/2017 Ovarian Cancer–Hot Topics in Surgical Treatment - Frailty and Surgical Complexity score in the decision making process 28th National Conference of the Italian Society of Gynecologic Oncology (SIOG) – Milano, Italy 01/19-20/2018 Palliative care: Surgical and nonsurgical management of acute or subacute bowel obstruction 2017 Progress and controversies in Gynecologic Oncology Conference - Barcelona, Spain 02/15-17/2018 LIVE surgery: radical debulking for advanced ovarian cancer

Master of disaster: complication in Senology and Gynecologic Oncology - Essen, Germany 05/01-02/2018 Vision in Newly Diagnosed Advanced Ovarian Cancer: from Concept to the Clinic - Discussant Vision & Innovation in Gynecological Cancer – 1st University of Navarra International Educational Meeting – Madrid, Spain 05/11/2018 Laparoscopy in interval debulking surgery in ovarian cancer - 6th MD Anderson International Meeting in Gynecologic Oncology: Embracing new standards of care in Gynecologic Cancers - Madrid, Spain 10/04/2018 The Role of Lymphadenectomy in the Management of Ovarian Cancer Memorial Sloan Kettering Cancer Center – State-of-the-Art Gynecologic Surgery & Ovarian Cancer Management – MSKCC, New York, USA 10/05-06/2018 Carcinoma ovarico - Ruolo della chirurgia nel carcinoma ovarico (PDS and IDS) - STRATEGIA INTEGRATA nel TRATTAMENTO delle NEOPLASIE GENITO URINARIE – Oliena (NU), Italy 11/22-24/2018 Tumor board on ovarian cancer Tumor board on cervical cancer 24° “HIGHLIGHTS IN GINECOLOGIA ONCOLOGICA” & 29° CONGRESSO NAZIONALE DELLA SOCIETà ITALIANA DI ONCOLOGIA GINECOLOGICA (SIOG) – Camogli (GE), Italy

Book Chapters 1. Aletti G . Surgery for Ovarian Cancer. Morrow CP Morrow’s Gynecologic Cancer

Surgery, Second Edition, © C. Paul Morrow, 2013 2. Aletti GD, Cliby WA. Primary Cytoreduction: Factors Impacting Operability and the

Extent of Surgery. Ayhan A, Reed N, Gultekin M, Dursun P. Textbook of Gynecologic Oncology, Second Edition. Günes publishing, 2012

3. Aletti GD, Cliby WA. Preoperative risk stratification and intraoperative supportive

care. Bristow RE, Karlan BY, Chi DS. Surgery for Ovarian Cancer, Third Edition. CRC Press, Taylor & Francis Group, 2016

4. Aletti GD, Cliby WA. Primary Cytoreduction: Factors Impacting Operability and the

Extent of Surgery. Ayhan A, Reed N, Gultekin M, Dursun P. Textbook of Gynecologic Oncology, Third Edition. Günes publishing, in press

5. Aletti GD, Carinelli S. Histopathology of gynaecological cancers. Du Bois A, Hall M,

Fotopoulou C, ESMO Gynecological Tumours Essentials, ESMO press 6. Aletti GD, Minig L, Zanagnolo V. Radical Pelvic and Retroperitoneal Surgery.

Ramirez P, Frumovitz M, Abu-Rustum N. Principles of Gynecologic Oncology Surgery,1st Edition, Elsevier

Articles 1. Frigerio L, Mariani A, Gandini L, Origoni M, Galli L, Rabaiotti E, Aletti G, Ferrari A.

Prognostic Factors in Patients with Locally Advanced Cervical Cancer Treated with Radical Hysterectomy and Adjuvant Radiotherapy. Int Surg, 1998; 83: 265-270.

2. Sier CFM, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, Casetta G, Stephens

RW, Brunner N, Blasi F. Presence of Urokinase-Type Plasminogen Activator Receptor in Urine of Cancer Patients and Its Possible Clinical Relevance. Lab Invest, 1999; 79(6): 717-722.

3. Quellari P, Mariani A, Aletti G, Villa G, Filippis S, Viganò R, Frigerio LG, Ferrari AG.

Polyteterafluoroethylene Mesh For Abdominal Hysterosacropexy: Long-Term Outcome Of A Conservative Approach Of Utero-Vaginal Prolapse. Eur J Pelvic Surg, 1999; 2(1): 35-41

4. Frigerio L, Mangili G, Aletti G, Carnelli M, Garavaglia E, Beatrice S, Ferrari A.

Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study. Gynecol Oncol. 2001;81(1):53-7.

5. Picchio M, Sironi S, Messa C, Mangili G, Landoni C, Gianolli L, Zangheri B, Vigano R,

Aletti G, de Marzi P, De Cobelli F, Del Maschio A, Ferrari A, Fazio F. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment.Q J Nucl Med. 2003;47(2):77-84

6. Sier CF, Nicoletti I, Santovito ML, Frandsen T, Aletti G, Ferrari A, Lissoni A, Giavazzi

R, Blasi F, Sidenius N. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb Haemost. 2004; 91(2):403-11

7. Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garavaglia E, Vigano R, Picchio M,

Taccagni G, Maschio AD, Fazio F. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology. 2004;233(2):433-40.

8. Mangili G, Aletti G, Frigerio L, Franchi M, Panacci N, Vigano R, DE Marzi P, Zanetto F,

Ferrari A. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer. 2005;15(5):830-5

9. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC,

Cliby WA. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77-85.

10. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Surgical treatment of diaphragm

disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol. 2006; 100(2):283-7.

11. Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability:

relative impact of disease, patient status and surgeon. Gynecol Oncol. 2006;100(1):33-7.

12. Aletti GD, Cliby WA. Importance of surgical aggressiveness in advanced ovarian

cancer. J Clin Oncol. 2006; 20;24(15):2397. 13. Aletti GD, Cliby WA. Is aggressive surgery beneficial only for patients with less

advanced ovarian cancer? A commentary on the international comparison within the SCOTROC-1 trial . Am J Oncol Rev. 2006; 5 (4): 200-202

14. Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney GL, Kalli KR, Staub J,

Ehrmann M, Cliby WA, Lee YK, Bible KC, Hartmann LC, Kaufmann SH, Shridhar V. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest. 2006; 116(7):1994-2004.

15. Aletti GD, Podratz KC, Jones MB, Cliby WA. Role of rectosigmoidectomy and

stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J Am Coll Surg. 2006; 203(4):521-6.

16. Aletti GD, Long HJ, Podratz KC, Cliby WA. Is time to chemotherapy a determinant

of prognosis in advanced-stage ovarian cancer? Gynecol Oncol. 2007; 104(1):212-6. 17. Cliby WA, Aletti GD, Wilson TO, Podratz KC. Is it justified to classify patients to

Stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol. 2006;103(3):797-801.

18. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Role of lymphadenectomy in the

management of grossly apparent advanced stage epithelial ovarian cancer. Am J Obstet Gynecol. 2006;195(6):1862-8.

19. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Analysis of factors impacting

operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol. 2007;105(1):84-9.

20. Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, Scheerer M, Roberts LR, Molina J,

Shridhar V. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene. 2007; 26;26(34):4969-78.

21. Cliby W, Aletti G. Surgical Management of Diaphragm Disease in Ovarian Cancer.

Operative Techniques in General Surgery, 2007; 9(2); 61-9. 22. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current Management

Strategies for Ovarian Cancer. Mayo Clin Proc. 2007; 82(6):751-770. 23. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, Bristow RE, Chi DS,

Cliby WA. A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107(1):99-106.

24. Chien J, Aletti G, Bell DA, Keeney GL, Shridhar V, Hartmann LC. Molecular

pathogenesis and therapeutic targets in epithelial ovarian cancer. J Cell Biochem. 2007; 1;102(5):1117-29.

25. Dearking AC, Aletti GD, McGree ME, Weaver AL, Sommerfield MK, Cliby WA. How

Relevant Are ACOG and SGO Guidelines for Referral of Adnexal Mass? Obstet Gynecol. 2007;110(4):841-8.

26. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical

complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007; 197(6):676.e1-7.

27. Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I,

Cliby WA. Müllerian inhibiting substance type II receptor (MISIIR): A novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol. 2008;108(1):141-8

28. Mangili G, Montoli S, De Marzi P, Sassi I, Aletti G, Aletti G, Taccagni G. The role of

DNA ploidy in postoperative management of stage I endometrial cancer. Ann Oncol. 2008;19(7):1278-83.

29. Dowdy SC, Loewen RT, Aletti G, Feitoza SS, Cliby W. Assessment of outcomes and

morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecol Oncol. 2008;109(2):303-7.

30. Aletti GD, Cliby WA. Primary Cytoreduction in Advanced Ovarian Cancer:

“Biological and Surgical Aggressiveness” Oncology. 2008; 22 (9): 1041-1045 31. Dowdy SC, Aletti G, Cliby WA, Podratz KC, Mariani A. Extra-peritoneal laparoscopic

para-aortic lymphadenectomy - A prospective cohort study of 293 patients with endometrial cancer. Gynecol Oncol. 2008;111(3):418-24.

32. Bakkum-Gamez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL,

O'Malley DM, Cliby WA. Influence of Intraoperative Capsule Rupture on Outcomes in Stage I Epithelial Ovarian Cancer. Obstet Gynecol. 2009;113(1):11-17.

33. Aletti GD, Podratz KC, Cliby WA, Gostout BS. Stage IV ovarian cancer: Disease site-

specific rationale for postoperative treatment. Gynecol Oncol. 2009;112(1):22-7. 34. Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long CH, Aggressive and Complex

Surgery for Advanced Ovarian Cancer: An Economic Analysis. Gynecol Oncol. 2009;112(1):16-21.

35. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC,

Cliby WA. Quality improvement (QI) in the surgical approach to advanced ovarian cancer (OC): the Mayo Clinic experience. J Am Coll Surg. 2009; 208 (4): 614-620

36. Aletti GD, Powless C, Bakkum-Gamez J, Wilson TO, Podratz KC, Cliby WA. Pattern of

retroperitoneal dissemination of primary peritoneum cancer: Basis for rational use of lymphadenectomy. Gynecol Oncol. 2009;114(1):32-6.

37. Uccella S, Podratz KC, Aletti GD, Mariani A. Lymphadenectomy in endometrial

cancer. Lancet. 2009;373(9670):1170; author reply 1170-1.

38. Chien J, Ota T, Aletti G, Shridhar R, Boccellino M, Quagliuolo L, Baldi A, Shridhar V.

Serine protease HtrA1 associates with microtubules and inhibits cell migration. Mol Cell Biol. 2009; 29(15):4177-87.

39. Uccella S, Podratz KC, Aletti GD, Mariani A. Re: Systematic Pelvic

Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial. 2009: 16;101(12):897-8.

40. Powless CA, Bakkum-Gamez JN, Aletti GD, Cliby WA. Random peritoneal biopsies

have limited value in staging of apparent early stage epithelial ovarian cancer after thorough exploration. Gynecol Oncol. 2009;115(1):86-9.

41. Heisler CA, Aletti GD, Weaver AL, Melton LJ 3rd, Cliby WA, Gebhart JB. Improving

quality of care: development of a risk-adjusted perioperative morbidity model for vaginal hysterectomy. Am J Obstet Gynecol. 2010; 202(2):137.e1-5.

42. Aletti GD, Nordquist D, Hartmann L, Gallenberg M, Long HJ, Cliby WA. From

randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer. Ann Oncol. 2010;21(9):1772-8.

43. Aletti GD, Hartmann LC. Ovarian cancer care: it's time for "personalized"

approaches. Oncology (Williston Park). 2010;24(8):728 44. Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F, Minig L, Biffi

R, Radice D, Maggioni A. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 2010;119(2):259-64.

45. Zapardiel I, Rosenberg P, Peiretti M, Zanagnolo V, Sanguineti F, Aletti G, Landoni F,

Bocciolone L, Colombo N, Maggioni A. The role of restaging borderline ovarian tumors: single institution experience and review of the literature. Gynecol Oncol. 2010;119(2):274-7.

46. Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, Chi DS,

Bristow RE, Cliby WA. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011;120(1):23-8.

47. Bakkum-Gamez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL,

O'Malley DM, Cliby WA. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Int J Gynecol Cancer. 2010; 20(7):1125-31.

48. Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA. Risk factors for lymph node

metastasis in apparent early-stage epithelial ovarian cancer: Implications for surgical staging. Gynecol Oncol. Gynecol Oncol. 2011;122(3):536-40.

49. Zecchini S, Bombardelli L, Decio A, Bianchi M, Mazzarol G, Sanguineti F, Aletti G,

Maddaluno L, Berezin V, Bock E, Casadio C, Viale G, Colombo N, Giavazzi R,

Cavallaro U. The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol Med. 2011; 3(8):480-94.

50. Langstraat C, Aletti GD, Cliby WA. Morbidity, mortality and overall survival in

elderly women undergoing primary surgical debulking for ovarian cancer: A delicate balance requiring individualization. Gynecol Oncol. 2011;123(2):187-91.

51. Zapardiel I, Peiretti M, Zanagnolo V, Biffi R, Bocciolone L, Landoni F, Aletti G,

Colombo N, Maggioni A. Diaphragmatic surgery during primary cytoreduction for advanced ovarian cancer: peritoneal stripping versus diaphragmatic resection. Int J Gynecol Cancer. 2011; 21(9):1698-703.

52. Cliby W, Aletti G, Chi D, Bristow R. RE: Defining the limits of radical cytoreductive

surgery in ovarian cancer. Gynecol Oncol. 2012;125(2):509-10; author reply 508-9. 53. Ceccaroni M, Roviglione G, Spagnolo E, Casadio P, Clarizia R, Peiretti M, Bruni F,

Peters I, Aletti G. Pelvic Dysfunctions and Quality of Life after Nerve-sparing Radical Hysterectomy: A Multicenter Comparative Study. Anticancer Res. 2012; 32(2):581-8.

54. Moslemi-Kebria M, El-Nashar SA, Aletti GD, Cliby WA. Intraoperative hypothermia

during cytoreductive surgery for ovarian cancer and perioperative morbidity. Obstet Gynecol. 2012;119(3):590-6.

55. Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F,

Bocciolone L, Aletti GD, Maggioni A. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol. 2012;126(2):220-3

56. Kalogera E, Dowdy SC, Mariani A, Aletti G, Bakkum-Gamez JN, Cliby WA. Utility of

Closed Suction Pelvic Drains at Time of Large Bowel Resection for Ovarian Cancer. Gynecol Oncol. 2012;126(3):391-6

57. Zapardiel I, Peiretti M, Zanagnolo V, Biffi R, Bocciolone L, Landoni F, Aletti G,

Colombo N, Maggioni A. Splenectomy as part of primary cytoreductive surgery for advanced ovarian cancer: a retrospective cohort study. Int J Gynecol Cancer. 2012;22(6):968-73.

58. Landoni F, Zanagnolo V, Rosenberg PG, Lopes A, Radice D, Bocciolone L, Aletti G,

Parma G, Colombo N, Maggioni A. Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience. Gynecol Oncol. 2013; 130(1):69-74

59. Kalogera E, Dowdy SC, Mariani A, Weaver AL, Aletti G, Bakkum-Gamez JN, Cliby WA.

Multiple large bowel resections: Potential risk factor for anastomotic leak. Gynecol Oncol. 2013;130(1):213-8.

60. Glaser G, Torres M, Kim B, Aletti G, Weaver A, Mariani A, Hartmann L, Cliby W. The

use of CT findings to predict extent of tumor at primary surgery for ovarian cancer. Gynecol Oncol. Gynecol Oncol. 2013;130(2):280-3

61. Zanagnolo V, Rollo D, Tomaselli T, Rosenberg PG, Bocciolone L, Landoni F, Aletti G,

Peiretti M, Sanguineti F, Maggioni A. Robotic-assisted transperitoneal aortic lymphadenectomy as part of staging procedure for gynaecological malignancies: single institution experience. Obstet Gynecol Int. 2013;2013:931318.

62. Garbi A, Colombo N, Aletti G. Summary of the 18th Biannual Meeting of the

European Society of Gynecologic Oncology (ESGO) Gynecol Oncol. 2014; 132(2):270-2

63. Zapardiel I, Diestro MD, Aletti G Conservative treatment of early stage ovarian

cancer: oncological and fertility outcomes. Eur J Surg Oncol. 2014;40(4):387-93. 64. Greggi S, Franchi M, Aletti G, Biglia N, Ditto A, Fagotti A, Giorda G, Mangili G,

Odicino F, Salerno MG, Vizza E, Scaffa C, Scollo P. Management of endometrial cancer in Italy: a national survey endorsed by the Italian Society of Gynecologic Oncology. Int J Surg. 2014;12(10):1038-44.

65. Bogani G, Cliby WA, Aletti GD. Impact of morcellation on survival outcomes of

patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol. 2015;137(1):167-72

66. Aletti GD, Bristow RE, Chi D, Cliby WA. There Is Nothing New Under the Sun. J Clin

Oncol. 2015; 20;33(30):3520. 67. Bogani G, Ditto A, Martinelli F, Lorusso D, Chiappa V, Donfrancesco C, Di Donato V,

Indini A, Aletti G, Raspagliesi F. Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma: A Systematic Review and Meta-analysis. Int J Gynecol Cancer. 2016; 26(2):371-80.

68. Zanagnolo V, Minig L, Rollo D, Tomaselli T, Aletti G, Bocciolone L, Landoni F,

Cardenas Rebollo JM, Maggioni A. Clinical and Oncologic Outcomes of Robotic Versus Abdominal Radical Hysterectomy for Women With Cervical Cancer: Experience at a Referral Cancer Center. Int J Gynecol Cancer. 2016; 26(3):568-74

69. Zanfagnin V, Ferrero A, Biglia N, Aletti G, Gill SE, Makdisi PB, Multinu F, Mariani A.

The role of surgery in recurrent endometrial cancer. Expert Rev Anticancer Ther. 2016;16(7):741-50

70. Aletti GD, Cliby WA. Time for centralizing patients with ovarian cancer: what are

we waiting for? Gynecol Oncol. 2016;142(2):209-10 71. Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G,

Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, du Bois A. European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery. Int J Gynecol Cancer. 2016; 26(7):1354-63.

72. Aletti GD, Peiretti M. Quality control in ovarian cancer surgery. Best Pract Res Clin

Obstet Gynaecol. 2016 Oct 1. [Epub ahead of print] Review

73. Di Donato V, Kontopantelis E, Aletti G, Casorelli A, Piacenti I, Bogani G, Lecce F,

Benedetti Panici P. Trends in Mortality After Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized Clinical Trials and Observational Studies. Ann Surg Oncol. 2016 Nov 28. [Epub ahead of print] Review.

74. Fotopoulou C, Sehouli J, Aletti G, Harter P, Mahner S, Querleu D, Chiva L, Gabra H,

Colombo N, du Bois A. Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. J Clin Oncol. 2017 Jan 9. [Epub ahead of print] No abstract available.

75. Gadducci A, Carinelli S, Aletti GD. Neuroendrocrine tumors of the uterine cervix: A

therapeutic challenge for gynecologic oncologists. Gynecol Oncol 2016, http://dx.doi.org/10.1016/j.ygyno.2016.12.003. 2017; 144(3):637-646.

76. Aletti GD, Garbi A, Messori P, Achilarre MT, Zanagnolo V, Rizzo S, Alessi S, Bocciolone L, Landoni F, Biffi R, Carinelli S, Colombo N, Maggioni A. Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit. Gynecol Oncol. 2017; 144(3):468-473.

77. Uccella S, Bonzini M, Malzoni M, Fanfani F, Palomba S, Aletti G, Corrado G, Ceccaroni

M, Seracchioli R, Shakir F, Ferrero A, Berretta R, Tinelli R, Vizza E, Roviglione G, Casarella L, Volpi E, Cicinelli E, Scambia G, Ghezzi F. The effect of a uterine manipulator on the recurrence and mortality of endometrial cancer: a multi-centric study by the Italian Society of Gynecological Endoscopy. Am J Obstet Gynecol. 2017 Jun;216(6):592.e1-592.e11.

78. Garbi A, Zanagnolo V, Colombo N, Aletti G, Achilarre MT, Bocciolone L, Landoni F,

Rizzo S, Biffi R, Maggioni A. Feasibility of Transabdominal Cardiophrenic Lymphnode Dissection in Advanced Ovarian Cancer: Initial Experience at a Tertiary Center. Int J Gynecol Cancer. 2017; 27(6):1268-1273.

79. Kumar A, Torres ML, Cliby WA, Kalli KR, Bogani G, Aletti G, Nitschmann CC, Multinu

F, Weaver AL, Block MS, Mariani A. Inflammatory and Nutritional Serum Markers as Predictors of Peri-operative Morbidity and Survival in Ovarian Cancer. Anticancer Res. 2017; 37(7):3673-3677

80. Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, Landoni F,

Lapresa MT, Maruccio M, Parma G, Peccatori F, Petrella MC, Zanagnolo V, Colombo N, Maggioni A. Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. Anticancer Res. 2017; 37(9):5241-5248.

81. Sangiorgio V, Zanagnolo V, Aletti G, Bocciolone L, Bruni S, Landoni F, Colombo N,

Maggioni A, Ricciardi E. Fibroblastic Malignant Peripheral Nerve Sheath Tumour of the Uterine Cervix: Report of a Case and Literature Review With Emphasis on Possible Differential Diagnosis. Int J Gynecol Pathol. 2018; 37(5):497-503.

82. Aletti GD. Lymphatic Spread of Ovarian Cancer: Can the Anatomical and Pathological Knowledge Help a Personalized Treatment? Ann Surg Oncol. 2018; 25(7):1791-1793.

83. Gadducci A, Carinelli S, Guerrieri ME, Aletti GD. Melanoma of the lower genital

tract: Prognostic factors and treatment modalities. Gynecol Oncol. 2018; 150(1):180-189

84. Rizzo S, Botta F, Raimondi S, Origgi D, Buscarino V, Colarieti A, Tomao F, Aletti G,

Zanagnolo V, Del Grande M, Colombo N, Bellomi M. Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months. Eur Radiol. 2018; 28(11):4849-4859.

PREMI/RICONOSCIMENTI PER MERITI SCIENTIFICI

1. SGS President’s award for outstanding research in Gynecologic Surgery 32rd Annual SGS Meeting Scientific Meeting. April 3-5, 2006. Tucson, AZ Awarded by Dr. Karl Podratz, MD, PhD. President

2. SGS President’s award for outstanding research in Gynecologic Surgery

33rd Annual SGS Meeting Scientific Meeting. April 12-14, 2007. Orlando FL By Dr. Peggy Norton, MD. President

3. Mayo Brothers Distinguished Fellowship Award for 2008

4. 2008 ASCO Foundation Merit Award – May 30- June 2, 2008. Chicago, IL

5. WAGO 2007 “J.G. Moore Award 2007” for outstanding paper on basic science

research. June 2007. Sunriver, OR

6. 6/19/2014: Certificate of Reviewing Excellence - Elsevier and the Editors of Gynecologic Oncology

7. May 2015: Certificate of Recognized reviewer - Critical Reviews in Oncology /

Hematology

8. August 2015: Certificate of Recognized reviewer – Gynecologic Oncology

9. June 2016: Certificate of Outstanding reviewer – Gynecologic Oncology

10. October 2016: Certificate of Recognized reviewer – American Journal of Obstetrics and Gynecology